OFFERING TORIGEN, A NEW WAY TO FIGHT CANCER
At Indian Trail Animal Hospital, we are staying on the cutting edge of companion animal oncology with a new Experimental Autologous Cancer Vaccine. By utilizing a portion of the animal’s own tumor tissue, a personalized treatment specific to the individual animal’s cancerous cells can be created. Treatments like this work to activate the immune system against specific tumor-associated antigens found on the outside surface of the tumor cells that are different than normal ‘self’ cells.
According to the American Veterinary Medical Association (AVMA) [page tag], almost 50% of deaths in dogs over 10 years of age can be attributed to cancer. Regular examinations can help catch problems in the early stages of development and increase the odds of your dog having a happy senior life. Torigen’s goal is to develop therapies that will help extend the lives of companion animals despite a cancer diagnosis. To learn more about their work and Experimental Autologous Cancer Vaccine, visit Torigen.com.
OFFERING SOLENSIA: ARTHRITIS PAIN MANAGEMENT FOR CATS
For years, there have been many options for dogs to treat pain. However, cats are a different story. Cats’ biology works differently and thus finding effective pain control has been a difficult journey.
Solensia is the only FDA approved treatment for osteoarthritis pain in felines. This is a type of arthritis that affects protective tissue in joints, causing it to wear down and allow bones to rub against one another.
When cats experience chronic pain, they often show Symptoms much differently than dogs and many times that pain causes behavioral problems, leading to many cats being returned to shelters.
Arthritis has been shown to affect up to 90% of cats past 2 years of age. Solensia has shown in studies that it not only helped cats control their arthritis pain, but also improved their quality of life and general well-being.
What is even better is that solensia is a once monthly injection given by your vet, so no pilling is involved!
Wondering if your cat could benefit? Go to the Cat OA Pain checklist quiz. https://bit.ly/OAChecklist
PennHIP, A MULTIFACETED RADIOGRAPH SCREENING METHOD FOR HIP EVALUATION BY OUR TRAINED VETERINARIAN DR. SUSAN SEETHALER, AS EARLY AS 16 WEEKS OF AGE TO PREDICT ONSET OF OSTEOARTHRITIS (OA)
The technique assesses the quality of the canine hip and quantitatively measures canine hip joint laxity. The PennHIP method of evaluation is more accurate than the current standard in its ability to predict the onset of osteoarthritis (OA). Osteoarthritis, also known as degenerative joint disease (DJD), is the hallmark of canine hip dysplasia (CHD). It causes pain and disability in dogs who have it.
PennHIP is more than just a radiographic technique. It is also a network of veterinarians trained to perform the PennHIP methodology properly. Perhaps most importantly, it is a large scientific database that houses the PennHIP data. Radiographs are made by certified PennHIP members worldwide and the images are sent to the PennHIP Analysis Center for evaluation. The resulting data is stored in the database, which is continually monitored as it expands. As more information becomes available, the PennHIP laboratory is able to obtain more precise answers to questions about the etiology, prediction and genetic basis of hip dysplasia.
OFFERING NON-SURGICAL MAST CELL TUMOR TREATMENT
Stelfonta is an innovative and effective treatment for Mast Cell Tumors in dogs. It is a prescription medicine used in dogs to treat mast cell tumors on the skin or in the tissues just under the skin. Given as an injection directly into your dog’s tumor, it destroys the tumor by breaking down cancer cells and starving their blood supply. It removes 75% of canine Mast Cell Tumors with a single treatment. 87% of dogs had a complete response after either one or two treatments combined. Please visit this site to help discuss with your veterinarian if Stelfonta may be the right treatment for your dog’s Mast Cell Tumor: https://stelfonta.com/Mast-cell-tumor-veterinarian-discussion-mobile.pdf